Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Citi
Cipla
Federal Trade Commission
Dow
McKinsey
Fish and Richardson
Healthtrust
Baxter

Generated: April 21, 2018

DrugPatentWatch Database Preview

NAMENDA XR Drug Profile

« Back to Dashboard

Which patents cover Namenda Xr, and what generic alternatives are available?

Namenda Xr is a drug marketed by Forest Labs Llc and is included in one NDA. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has sixty-nine patent family members in nineteen countries.

The generic ingredient in NAMENDA XR is memantine hydrochloride. There are twenty-eight drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the memantine hydrochloride profile page.
Summary for NAMENDA XR
Drug patent expirations by year for NAMENDA XR
Pharmacology for NAMENDA XR
Medical Subject Heading (MeSH) Categories for NAMENDA XR
Synonyms for NAMENDA XR
(3,5-Dimethyl-1-adamantyl)amine hydrochloride
1-amino-3,5-dimethyl-adamantane hydrochloride
1-Amino-3,5-dimethyladamantane Hydrochloride
1,3-Dimethylaminoadamantane hydrochloride
19982-08-2 (Parent)
3,5-Dimethyl-1-adamantanamine hydrochloride
3,5-Dimethyl-1-adamantanamineHydrochloride
3,5-Dimethyl-1-aminoadamantane HCl
3,5-Dimethyl-1-aminoadamantane hydrochloride
3,5-Dimethyl-tricyclo[3.3.1.13,7]decan-1-amine hydrochloride
3,5-dimethyladamantan-1-amine hy-drochloride
3,5-dimethyladamantan-1-amine hydrochloride
3,5-dimethyladamantan-1-amine;hydrochloride
3,5-dimethyladamantan-1-aminium chloride
3,5-dimethyladamantanylamine, chloride
3,5-Dimethylamantadine hydrochloride
3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine hydrochloride
3,5-Dimethyltricyclo(3.3.1.1(sup 3,7))decan-1-amine hydrochloride
3,5-Dimethyltricyclo(3.3.1.13,7)decan-1-amine hydrochloride
3,5-dimethyltricyclo[3.3.1.13,7]decan-1-amine hydrochloride
41100-52-1
4CH-006120
AB0013351
AB2000447
AC-559
AC1L492E
ACMC-209jif
AK-44671
Akatinol
AKOS015889460
AM20070534
AN-15700
ANW-29557
AOB5318
AS-13331
AX8033628
Axura
BC208848
BCP9000253
BG0374
BR-44671
CCG-39018
CHEBI:64323
CHEMBL1699
CPD000058926
CPD000875213
CS-2422
CTK8B1656
D 145
D-145
D04905
D3608
Ebixa
Ebixza
EINECS 255-219-6
EU-0100861
FT-0650723
H908
HMS1571C17
HMS1921H03
HY-B0365A
I01-2072
J10287
JY0WD0UA60
KS-00000X1M
KSC911M5N
LDDHMLJTFXJGPI-UHFFFAOYSA-N
LP00861
M 9292
M-2015
Mantine
MCULE-6635165082
Memantin hydrochloride
Memantine (hydrochloride)
Memantine HCL
MEMANTINE HYDROCHLORIDE
Memantine hydrochloride (JAN/USAN)
Memantine hydrochloride (Namenda)
Memantine hydrochloride [USAN]
memantine.HCl
Memantinehydrochloride
Memary
Memary (TN)
MFCD00214336
MLS001332605
MLS001332606
MolPort-003-666-358
MRZ-2/145
N06DX01
Namenda
Namenda (TN)
NC00680
NCGC00094186-01
NCGC00094186-02
NCGC00094186-03
NCGC00261546-01
NMI-131
NSC 102290
NSC-102290
NSC-757843
NSC102290
NSC757843
Pharmakon1600-01501121
RTR-016345
s2043
SAM001246743
SAM002699890
SBB003390
SCHEMBL3053
SMR000875213
SPECTRUM1501121
SR-01000075458
SR-01000075458-1
ST088119
SUN Y7017
SUN-Y7017
Tox21_500861
TR-016345
Tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-, hydrochloride
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine, 3,5-dimethyl-, hydrochloride
UNII-JY0WD0UA60
Z1551429722

US Patents and Regulatory Information for NAMENDA XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-001 Jun 21, 2010 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-003 Jun 21, 2010 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NAMENDA XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-001 Jun 21, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-002 Jun 21, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-003 Jun 21, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NAMENDA XR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-08-16
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg ➤ Subscribe 2013-06-17
➤ Subscribe Extended-release Capsules 28 mg ➤ Subscribe 2013-06-12
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-06-10

Non-Orange Book US Patents for NAMENDA XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,619,007 Method and composition for administering an NMDA receptor antagonist to a subject ➤ Try a Free Trial
8,058,291 Methods and compositions for the treatment of CNS-related conditions ➤ Try a Free Trial
8,293,794 Methods and compositions for the treatment of CNS-related conditions ➤ Try a Free Trial
2,012,045,508 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for NAMENDA XR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02C/035 Belgium ➤ Try a Free Trial PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
C/GB02/046 United Kingdom ➤ Try a Free Trial PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
Queensland Health
Chubb
Deloitte
Cipla
McKinsey
Federal Trade Commission
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.